Objective: A novel coronavirus infection (SARS-CoV-2) pneumonia (COVID-19) has been quickly spreading throughout China and the rest of the world since December 2019. Respiratory tract infections are frequently linked to diabetes mellitus (DM), a different risk factor. This study has reported the clinical presentation and therapeutic outcomes of COVID-19 with diabetes. Methods: From medical records and histories provided by 72 Covid-19-infected patients with diabetes admitted to the KMCH institute of health sciences and research, Coimbatore, data on demographics, clinical, laboratory, and radiological characteristics as well as treatment outcomes were collected using data collection forms. Real-time reverse transcription polymerase chain reaction (RT-PCR) assay of 2019-CoV RNA was used to screen patients with Covid-19. Results: 72 diabetes patients who tested positive for Covid-19 were admitted for this study. SPSS software version 26 was used to evaluate the data that had been collected. Clinical profiles and outcomes of patients with and without diabetes underwent descriptive analysis. Controlled diabetics had a mean plasma glucose of 112.22±11.41, while uncontrolled diabetics had a mean plasma glucose of 154.2±23.22. Fever was the most prevalent symptom in both managed and uncontrolled diabetes patients (94% and 100%), followed by sore throat (84% and 88%). In patients with uncontrolled diabetes compared to those with controlled diabetes, breathlessness is considerably higher (p<0.05). In the CORADS scoring, 11 of the 34 diabetics with uncontrolled blood sugar levels had CORADS 6 (32.35%), compared to just 2 of the 38 diabetics with regulated blood sugar levels (5.26%), which is considerably higher (p<0.01). In uncontrolled diabetics, the length of hospital stay is much longer (p<0.001). Compared to diabetics with controlled blood sugar, uncontrolled patients SPO2 dramatically dropped (p<0.001). Those with uncontrolled diabetes are more likely to be admitted to the ICU than patients with controlled diabetes (p<0.05). In uncontrolled diabetes compared to controlled patients, the severity was considerably higher (p<0.05). One person who had uncontrolled diabetes died, although no one who had controlled diabetes died. Conclusion: Covid 19, persons with uncontrolled diabetes appear to be more likely to sustain lung damage, necessitating admission to the ICU, an extended stay in the hospital, and oxygen assistance throughout the duration of the illness.

Objective: Plumeria alba (Apocynaceae), commonly known as “Frangipani” is an important medicinal plant, widely distributed throughout Southern India. In the traditional medicinal system, different parts of this plant have been mentioned to be useful in a wide variety of diseases. In this study, analgesic activity of aqueous and alcoholic extract of flowers of P. alba Linn was evaluated by hot-plate and acetic acid-induced writhing methods to substantiate and expand its clinical applications. Methods: The flowers of P. alba were collected from the local area in and around Coimbatore (India). The flowers were dried, powdered, and were extracted using soxhlet apparatus for 12 h using water and 95% of ethanol as a solvent. The test extracts were administered orally at a dose of 100 & 200 mg/kg while diclofenac sodium (10 mg/kg) served as standard. Results: The ethanolic flower extract of 200 mg/kg had significant analgesic activity in acetic acid-induced abdominal writhing response (***p<0.001) when compared to control and standard drug diclofenac. It also exhibited significant analgesic activity (***p<0.001) by increasing the pain reaction time of the rats in comparison to control and standard in hot plate method. Conclusion: The results suggest that ethanolic flower extracts of P. alba possess potent analgesic properties, which support its use in traditional medicine and suggesting that the plant should be further investigated for its pharmacological active natural products.

Background: Pain is the first and foremost symptom which alerts us about the underlying diseases, injuries or inflammation. Varied treatments are followed for pain relief worldwide. Nowadays tramadol, a centrally acting opioid analgesic is used widely. There are evidences that sweet substances like sucrose produce analgesia through endogenous opioid system. Sucrose has been proved to produce analgesic effect in healthy neonates and also in animals. Likewise, analgesic effect of glucose has also been studied but only limited no. of studies available. Methods: Swiss Albino mice of either sex (20-30g) were procured from the central animal house of KFMS and R, Coimbatore. Animals were maintained under controlled temperature and light conditions with food and water ad libitum. Mice were kept in the department to get acclimatized. 24 mice were divided into 4 groups (n=6). Drugs were given orally after 12hours of fasting. Group I was the control. Group II received standard-tramadol (40mg/kg). Group III received glucose (200mg/kg). Group IV received glucose (400mg/kg). Results: The latency period of glucose was significant (p<0.001) compared to controls and standard was significant (p<0.001) when compared to glucose by hot plate method. Conclusions: Analgesic activity of glucose may be due to both central and peripheral inhibition of PG synthesis. This has been proved in previous studies. This study showed that glucose can be used as an add-on in non-diabetic patients with better compliance.

Background: Considering the overwhelming medical, economic, and social consequences of coronavirus disease 2019 (COVID-19) safe and effective prophylactic vaccines were rolled out in India on January 16, 2021. Although the discussions surrounding the efficacy of the vaccines are greatly explored, safety concerns regarding post-marketing surveillance have not been studied in detail. Aims and Objectives: The study aims to assess the post-vaccination events to the first and second doses of COVID-19 vaccine and to evaluate the adverse effects (AEs) profile of the individual COVID-19 vaccines among COVID-19 vaccinated participants. Materials and Methods: Retrospective, cross-sectional online survey, was conducted among COVID-19 vaccinated participants from June 2021 to December 2021 at a tertiary care hospital, in Coimbatore. Data obtained through Google forms were analyzed using statistical package for the social sciences version 26. Results: Of the 95 responses received, 93.2% had an adverse events following immunization (AEFI). Pain at the injection site (74.74%), general unwell feeling (51.58%), and fever/chills (44.21%) were the commonly reported AEs. AEFI was higher with the first dose (53.5%) compared to the second dose (39.7%). Among the factors associated with AEFI, except the history of (H/O) medication for acute/chronic illnesses, there were no statistically significant differences between gender, COVID-19 infection in the past, H/O drug/food allergy, type of vaccine, and comorbidities. Conclusion: Most of the AEFIs were mild, and both the viral vector and inactivated vaccine were found to be safe. Hence, the COVID-19 vaccination should be recommended to counteract the severity of the disease.